论文部分内容阅读
曲格列酮（troglitazone，Rezulin－ParkeDavis公司）是新一类噻唑烷二酮衍生物中第一个上市用于非胰岛素依赖型糖尿病患者的的口服治疗药，这些病人每日需服用胰岛素30U，糖化血红蛋白（HbA1c）浓度仍在8.5或更高。1非胰岛素依赖型糖尿病治疗药物当非胰岛素依赖型糖尿病病人用
Troglitazone (Rezulin-Parke Davis) is the first of a new class of thiazolidinedione derivatives to be used in oral therapy for patients with non-insulin-dependent diabetes mellitus. These patients need to take insulin 30 U daily, Glycosylated hemoglobin (HbA1c) concentration is still 8.5 or higher. 1 Non-insulin-dependent diabetes treatment When non-insulin-dependent diabetes patients